FORMULARY EXCEPTION POLICY

POLICY: Mavyret® (glecaprevir/pibrentasvir tablets – AbbVie)

DATE REVISED: 10/02/2019

Documentation: Documentation will be required for patients requesting Mavyret where noted in the criteria as [documentation required]. Documentation may include, but is not limited to, chart notes, prescription claims records, prescription receipts and/or laboratory data.

CRITERIA

1. Hepatitis C virus (HCV) any genotype. Patients who meet any of the following criteria do not qualify for treatment with Mavyret (A, B, C, or D): [Note: for patients who do not meet one of the following criteria A through D, review using the appropriate criteria 2 through 8 below]:
   A. Combination use with direct-acting antivirals (DAAs); OR
   B. Life expectancy < 12 months due to non-liver related comorbidities; OR
   C. Child-Pugh Class B or C liver disease (severe hepatic impairment); OR
   D. Pediatric patients < 12 years of age or < 45 kg.

2. Chronic Hepatitis C Virus (HCV) Genotype 1: Approve Mavyret for the duration specified below if the patient meets the following criteria (A, B, and C):
   A. The patient is ≥ 12 years of age or ≥ 45 kg; AND
   B. Mavyret is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician; AND
   C. The patient meets ONE of the following conditions (i, ii, or iii)
      i. Condition 1: Approve for up to 12 weeks if the patient meets ONE of a or b and c:
         a) The patient is treatment-naïve; OR
         b) The patient has previously been treated with pegylated interferon/ribavirin, Incivek, Olysio, or Victrelis; AND
         c) The patient has completed a course of therapy with ONE of Epclusa (brand or generic), Harvoni (brand or generic), or Zepatier and has documentation that he/she did not achieve a sustained viral response (SVR; virus undetectable 12 weeks following completion of therapy) [documentation required]. OR
      ii. Condition 2: Approve for 16 weeks if the patient meets the following criteria (a and b):
         a) The patient has previously been treated with Daklinza, Epclusa (brand or generic), Harvoni (brand or generic), or Zepatier; AND
         b) The patient has completed a course of therapy with Vosevi and has documentation that he/she did not achieve a sustained viral response (SVR; virus undetectable 12 weeks following completion of therapy) [documentation required]. OR
      iii. Condition 3: Approve for up to 16 weeks if the patient meets the following criteria (a or b):
         a) The patient has previously been treated with Sovaldi + ribavirin with or without pegylated interferon/interferon; OR
         b) The patient has previously been treated with Sovaldi + Olysio.

3. Chronic Hepatitis C Virus (HCV) Genotype 2, Adults (≥ 18 years of age). Approve Mavyret for up to 12 weeks if the patient meets the following criteria (A, B, and C):
   A. The patient is ≥ 18 years of age; AND
B. Mavyret is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician; AND

C. The patient meets ONE of the following conditions (i or ii):
   i. **Condition 1**: The patient meets ONE of a or b and c:
      a) The patient is treatment-naïve; OR
      b) The patient has previously been treated with pegylated interferon/ribavirin; AND
      c) The patient has completed a course of therapy with Epclusa (brand or generic) and has documentation that he/she did not achieve a sustained viral response (SVR; virus undetectable 12 weeks following completion of therapy) [documentation required]. OR
   
   ii. **Condition 2**: The patient meets the following criteria (a):
      a) The patient has previously been treated with Sovaldi + ribavirin with or without pegylated interferon/interferon.

4. **Chronic Hepatitis C Virus (HCV) Genotype 2, Pediatrics (≥ 12 years of age or ≥ 45 kg)**. Approve Mavyret for 12 weeks if the patient meets the following criteria (A and B):
   A. The patient is ≥ 12 years of age OR ≥ 45 kg; AND
   B. Mavyret is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician.

5. **Chronic Hepatitis C Virus (HCV) Genotype 3, Adults (≥ 18 years of age)**. Approve Mavyret for the specified duration if the patient meets the following criteria (A, B, and C):
   A. The patient is ≥ 18 years of age; AND
   B. Mavyret is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician; AND
   C. The patient meets ONE of the following conditions (i, ii or iii)
      i. **Condition 1**: Approve for up to 12 weeks if the patient meets the following criteria (a and b):
         a) The patient is treatment-naïve; AND
         b) The patient has completed a course of therapy with Epclusa (brand or generic) and has documentation that he/she did not achieve a sustained viral response (SVR; virus undetectable 12 weeks following completion of therapy) [documentation required]. OR
      
      ii. **Condition 2**: Approve for 16 weeks if the patient meets the following criteria (a and b):
         a) The patient has previously been treated with Sovaldi + ribavirin with or without pegylated interferon/interferon; AND
         b) The patient has completed a course of therapy with Vosevi and has documentation that he/she did not achieve a sustained viral response (SVR; virus undetectable 12 weeks following completion of therapy) [documentation required]. OR
      
      iii. **Condition 3**: Approve for up to 16 weeks if the patient meets the following criteria (a and b):
         a) The patient has previously been treated with pegylated interferon/ribavirin; AND
         b) The patient has completed a course of therapy with Epclusa (brand or generic) and has documentation that he/she did not achieve a sustained viral response (SVR; virus undetectable 12 weeks following completion of therapy) [documentation required].

6. **Chronic Hepatitis C Virus (HCV) Genotype 3, Pediatric (≥ 12 years of age OR ≥ 45 kg)**. Approve Mavyret for the specified duration if the patient meets the following criteria (A, B, and C):
   A. The patient is ≥ 12 years of age OR ≥ 45 kg; AND
   B. Mavyret is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician; AND

© 2019 Express Scripts Holding Company. All Rights Reserved.
This document is proprietary and confidential to Express Scripts Holding Company. Unauthorized use and distribution are prohibited.
C. The patient meets ONE of the following (i or ii):
   i. **Condition 1**: Approve for up to 12 weeks if the patient meets the following criteria (a):
      a) The patient is treatment-naïve; OR
   ii. **Condition 2**: Approve for up to 16 weeks if the patient meets the following criteria (a or b):
      a) The patient has previously been treated with Sovaldi + ribavirin with or without pegylated interferon/interferon; OR
      b) The patient has previously been treated with pegylated interferon/ribavirin.

7. **Chronic Hepatitis C Virus (HCV) Genotype 4.** Approve Mavyret for 12 weeks if the patient meets the following criteria (A, B, and C):
   A. The patient is ≥ 18 years of age; AND
   B. Mavyret is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician; AND
   C. The patient meets ONE of the following conditions (i or ii)
      i. **Condition 1**: The patient meets ONE of a or b and c:
         a) The patient is treatment-naïve; OR
         b) The patient has previously been treated with pegylated interferon/ribavirin; AND
         c) The patient has completed a course of therapy with Epclusa (brand or generic), Harvoni (brand or generic), or Zepatier and has documentation that he/she did not achieve a sustained viral response (SVR; virus undetectable 12 weeks following completion of therapy) [documentation required]. OR
      ii. **Condition 2**: The patient meets the following criteria (a):
         a) The patient has previously been treated with Sovaldi + ribavirin with or without pegylated interferon/interferon.

8. **Chronic Hepatitis C Virus (HCV) Genotype 5 or 6.** Approve Mavyret for 12 weeks if the patient meets the following criteria (A, B, and C):
   A. The patient is ≥ 12 years of age or ≥ 45 kg; AND
   B. Mavyret is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician; AND
   C. The patient meets ONE of the following conditions (i or ii)
      i. **Condition 1**: The patient meets ONE of a or b and c:
         a) The patient is treatment-naïve; OR
         b) The patient has previously been treated with pegylated interferon/ribavirin; AND
         c) The patient has completed a course of therapy with Epclusa (brand or generic) or Harvoni (brand or generic) and has documentation that he/she did not achieve a sustained viral response (SVR; virus undetectable 12 weeks following completion of therapy) [documentation required]. OR
      ii. **Condition 2**: The patient meets the following criteria (a):
         a) The patient has previously been treated with Sovaldi + ribavirin with or without pegylated interferon/interferon.

9. **Hepatitis C Virus (HCV) Genotype 1, Renal Impairment (estimated glomerular filtration rate [eGFR] < 30 mL/min or end-stage renal disease [ESRD]):** Approve Mavyret for the duration specified below if the patient meets all of the following criteria (A, B, and C):
   A. The patient is ≥ 12 years of age or ≥ 45 kg; AND
   B. Mavyret is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, nephrologist, kidney transplant physician, or a liver transplant physician; AND
   C. The patient meets ONE of the following conditions (i or ii)
      i. **Condition 1**: Approve for up to 12 weeks if the patient meets ONE of a or b and c:
         a) The patient is treatment-naïve; OR
b) The patient has previously been treated with pegylated interferon/ribavirin, Incivek, Olysio, or Victrelis; AND

c) The patient has completed a course of therapy with Zepatier and has documentation that he/she did not achieve a sustained viral response (SVR; virus undetectable 12 weeks following completion of therapy) [documentation required]. OR

ii. Condition 2: Approve for 16 weeks if the patient meets ONE of the following criteria (a, b, or c):

a) The patient has previously been treated with Daklinza, Epclusa (brand or generic), Harvoni (brand or generic), or Zepatier; OR

b) The patient has previously been treated with Sovaldi + ribavirin with or without pegylated interferon/interferon; OR

c) The patient has previously been treated with Sovaldi + Olysio.

10. Hepatitis C Genotype 4 with Renal Impairment (estimated glomerular filtration rate [eGFR] < 30 mL/min or end-stage renal disease [ESRD]): Approve Mavyret for up to 12 weeks if the patient meets all of the following criteria (A, B, and C):

A. The patient is ≥ 12 years of age or ≥ 45 kg; AND

B. Mavyret is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, nephrologist, kidney transplant physician, or a liver transplant physician; AND

C. The patient meets ONE of the following conditions (i or ii)

i. Condition 1: The patient meets ONE of a or b and c:

a) The patient is treatment-naïve; OR

b) The patient has previously been treated with pegylated interferon/ribavirin; AND

c) The patient has completed a course of therapy with Zepatier and has documentation that he/she did not achieve a sustained viral response (SVR; virus undetectable 12 weeks following completion of therapy) [documentation required]. OR

ii. Condition 2: The patient meets the following criteria (a):

a) The patient has previously been treated with Sovaldi + ribavirin with or without pegylated interferon/interferon.

11. Hepatitis C Genotype 2, 3, 5, or 6 with Renal Impairment (estimated glomerular filtration rate [eGFR] < 30 mL/min or end-stage renal disease [ESRD]): Approve Mavyret for the duration specified below if the patient meets all of the following criteria (A, B, and C):

A. The patient is ≥ 12 years of age or ≥ 45 kg; AND

B. Mavyret is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, nephrologist, kidney transplant physician, or a liver transplant physician; AND

C. The patient meets ONE of the following (i, ii, or iii):

i. The patient has genotype 2, 5, or 6: Approve for 12 weeks.

ii. The patient has genotype 3 and is treatment-naïve: Approve for 12 weeks.

iii. The patient has genotype 3 and has previously been treated: Approve for 16 weeks.

12. Hepatitis C Virus (HCV) Genotype 1, Kidney Transplant: Approve Mavyret for the duration specified below if the patient meets all of the following criteria (A, B, C, and D):

A. The patient is ≥ 12 years of age or ≥ 45 kg; AND

B. The patient is a kidney transplant recipient; AND

C. Mavyret is prescribed by or in consultation with one of the following prescribers who is affiliated with a transplant center: gastroenterologist, hepatologist, infectious diseases physician, nephrologist, renal transplant physician, or liver transplant physician.

D. The patient meets ONE of the following conditions (i or ii)

i. Condition 1: Approve for 12 weeks if the patient meets the following criteria (a and b):

a) The patient is treatment-naïve; AND
b) The patient has completed a course of therapy with Harvoni (brand or generic) and has documentation that he/she did not achieve a sustained viral response (SVR; virus undetectable 12 weeks following completion of therapy) \[\text{documentation required}\].

OR

ii. Condition 2: Approve for 16 weeks if the patient meets the following criteria (a):

a) The patient has previously been treated for HCV.

13. Hepatitis C Virus (HCV) Genotype 2, 3, 5, or 6, Kidney Transplant: Approve Mavyret for the duration specified below if the patient meets all of the following criteria (A, B, C, and D):

A. The patient is \(\geq 12\) years of age or \(\geq 45\) kg; AND

B. The patient is a kidney transplant recipient; AND

C. Mavyret is prescribed by or in consultation with one of the following prescribers who is affiliated with a transplant center: gastroenterologist, hepatologist, infectious diseases physician, nephrologist, renal transplant physician, or liver transplant physician.

D. The patient meets ONE of the following conditions (i, ii, or iii):

i. The patient has genotype 2, 5, or 6: Approve for 12 weeks.

ii. The patient has genotype 3 and is treatment-naïve: Approve for 12 weeks.

iii. The patient has genotype 3 and has previously been treated for HCV: Approve for 16 weeks.

14. Hepatitis C Virus (HCV) Genotype 4, Kidney Transplant: Approve Mavyret 12 weeks if the patient meets all of the following criteria (A, B, C, and D):

A. The patient is \(\geq 12\) years of age or \(\geq 45\) kg; AND

B. The patient is a kidney transplant recipient; AND

C. Mavyret is prescribed by or in consultation with one of the following prescribers who is affiliated with a transplant center: gastroenterologist, hepatologist, infectious diseases physician, nephrologist, renal transplant physician, or liver transplant physician.

D. The patient meets ONE of the following conditions (i or ii):

i. Condition 1: The patient meets the following criteria (a and b):

   a) The patient is treatment-naïve; AND

   b) The patient has completed a course of therapy with Harvoni (brand or generic) and has documentation that he/she did not achieve a sustained viral response (SVR; virus undetectable 12 weeks following completion of therapy) \[\text{documentation required}\].

   OR

ii. Condition 2: The patient meets the following criteria (a):

   a) The patient has previously been treated for HCV.

15. Hepatitis C Virus (HCV) Genotype 1, 2, 3, 4, 5, or 6, Liver Transplant: Approve Mavyret for the duration specified below if the patient meets all of the following criteria (A, B, C, and D):

A. The patient is \(\geq 12\) years of age or \(\geq 45\) kg; AND

B. The patient is a liver transplant recipient; AND

C. Mavyret is prescribed by or in consultation with one of the following prescribers who is affiliated with a transplant center: gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician; AND

D. The patient meets ONE of the following (i or ii):

i. The patient has genotype 2, 4, 5, or 6: Approve for 12 weeks.

ii. The patient has genotype 1 or 3 and is treatment-naïve: Approve for 12 weeks.

iii. The patient has genotype 1 or 3 and has previously been treated for HCV: Approve for 16 weeks.

16. Recurrent Hepatitis C Virus Post-Liver Transplantation, Genotype 1, 4, 5, or 6: Approve Mavyret for 12 weeks in patients who meet the following criteria (A, B, C, and D):

© 2019 Express Scripts Holding Company. All Rights Reserved.
This document is proprietary and confidential to Express Scripts Holding Company. Unauthorized use and distribution are prohibited.
A. The patient is ≥ 12 years of age or ≥ 45 kg; AND
B. The patient is a liver transplant recipient; AND
C. Mavyret is prescribed by or in consultation with one of the following prescribers who is affiliated with a transplant center: gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician; AND
D. The patient has completed a course of therapy with Harvoni (brand or generic) and has documentation that he/she did not achieve a sustained viral response (SVR; virus undetectable 12 weeks following completion of therapy) [documentation required].

17. Recurrent Hepatitis C Virus Post-Liver Transplantation, Genotype 2 or 3: Approve Mavyret for 12 weeks in patients who meet the following criteria (A, B, and C):
   A. The patient is ≥ 12 years of age or ≥ 45 kg; AND
   B. The patient has recurrent HCV after a liver transplantation; AND
   C. Mavyret is prescribed by or in consultation with one of the following prescribers who is affiliated with a transplant center: gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician.

18. Patient Has Been Started on Mavyret. Approve for an indication or condition above. Approve the duration described above to complete a course therapy (e.g., a patient who should receive 12 weeks, and has received 3 weeks should be approved for 9 weeks to complete their 12-week course).

HISTORY

<table>
<thead>
<tr>
<th>Type of Revision</th>
<th>Summary of Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Policy</td>
<td>--</td>
</tr>
<tr>
<td>DEU revision</td>
<td>Added generics to Harvoni and Epclusa where applicable.</td>
</tr>
<tr>
<td>DEU revision</td>
<td>Added criteria for pediatric patients ≥ 12 years of age or ≥ 45 kg to all approval conditions. The exclusion criterion for pediatric patients (age &lt; 18 years) was updated to &lt; 12 years of age or &lt; 45 kg.</td>
</tr>
<tr>
<td>DEU revision</td>
<td>Child Pugh Class B added to exclusions</td>
</tr>
</tbody>
</table>